ABSTRACT Glucagon-like peptide-1 (GLP-1) is a hormone of the incretin system
responsible for a variety of glucoregulatory effects, including glucose-dependent secretion of …

Abstract Glucagon-like peptide-1 (GLP-1) is a gastrointestinal hormone, secreted in
response to ingestion of nutrients, and has important effects on several of the …

The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP) are physiological gut peptides with insulin-releasing and …

The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP) are released from enteroendocrine cells in response to the …

What is known and objective Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are
one of the preferred approved treatment options for people with type 2 diabetes (T2D) and …

Type 2 diabetes mellitus (T2DM) is a progressive multisystemic disease that increases
significantly cardiovascular morbidity and mortality. It is associated with obesity, insulin …

Although several classes of pharmacotherapy are available for type 2 diabetes, glycaemic
control is often hampered by medication‐related adverse effects and contraindications such …

Glucagon‐like peptide 1 (GLP‐1) is a gut‐derived incretin hormone with the potential to
change diabetes. The physiological effects of GLP‐1 are multiple, and many seem to …

Glucagon-like peptide 1 (GLP-1) was discovered as an insulinotropic gut hormone,
suggesting a physiological role as an incretin hormone, ie, being responsible, in part, for the …

Obective Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are indicated for treatment of
type 2 diabetes since they mimic the actions of native GLP‐1 on pancreatic islet cells …